Skip to main
USPH

USPH Stock Forecast & Price Target

USPH Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

US Physical Therapy is expected to continue generating strong revenue, with increased profitability from a growing industrial injury prevention segment and potential M&A opportunities in both PT and IIP. However, risks include potential wage pressure, Medicare reimbursement pressure, and economic contraction affecting demand for PT services. Estimates for 2026 and 2027 project revenue of $836.4M and $878.0M, respectively, with EBITDA of $104M in 2026 and $120M in 2027. The recent acquisition of an eight-clinic PT practice and a 70% interest in an IIP business, as well as continued de novo clinic openings, show strategic growth potential for the company.

Bears say

US Physical Therapy is currently facing headwinds from adverse weather conditions, which have affected its revenue in the first quarter of 2026. Its recent financial results showed improvement in same-store visits and revenue from its Industrial Injury Prevention segment. While the company has promising partnerships with hospitals, its valuation has been compressed in the past few years and may not justify a high target price at this time. Overall, there are concerns about the company's ability to sustain growth and generate strong profits in the near future, leading to a negative outlook on its stock.

USPH has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About U.S. Physical Therapy (USPH) Forecast

Analysts have given USPH a Buy based on their latest research and market trends.

According to 4 analysts, USPH has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

U.S. Physical Therapy (USPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.